All articles tagged with #type 2 diabetes
An oncologist highlights six research-backed benefits of daily black coffee — potential lower risk of premature death, reduced risk of several chronic diseases, liver protection, lower diabetes risk, possible cancer associations, and brain health support — while stressing that these are associations, caffeine tolerance varies, and coffee should complement, not replace, good sleep, exercise, and a healthy diet.
Maryland-based physician Dr. Kunal Sood highlighted six signs of insulin resistance—increasing belly fat, darkened skin folds (acanthosis nigricans), fatigue after meals, cravings for carbs, skin tags, and increased thirst—explaining these symptoms reflect elevated insulin and signal risk for prediabetes and type 2 diabetes, underscoring the importance of early attention.
An observational study of about 53,000 people with type 2 diabetes and established heart disease found tirzepatide (Mounjaro) was associated with a 33% lower risk of major cardiovascular events, including heart attack, over roughly one year compared with sitagliptin; 2.9% vs 4.4% event rates, roughly one event prevented per 70 new tirzepatide users. The findings add to evidence GLP-1 meds may support heart health, but the study’s observational design and short follow-up limit conclusions, and tirzepatide is not FDA-approved for cardiac risk reduction.
An oncologist, Dr. Vartika Vishwani, says she drinks black coffee daily and highlights six benefits—lower risk of death, reduced risk of chronic diseases, liver protection, lower risk of type-2 diabetes, potential cancer risk reduction, and brain health—while cautioning that coffee isn’t for everyone. She recommends moderate intake (roughly 2–4 cups per day, ~300–400 mg caffeine) and consulting a doctor if you have anxiety or heart rhythm disorders, and reminds that coffee cannot replace sleep, exercise, or a healthy diet.
A BMJ study led by the University of Pennsylvania finds that GLP-1 receptor agonists used for obesity and type 2 diabetes are linked to a higher risk of non-scarring hair loss compared with SGLT-2 and DPP-4 inhibitors, though the absolute risk is small (about 7 in 1,000 per year). The researchers suggest rapid weight loss and nutritional changes as potential mechanisms and call for more research, while noting the need to weigh this potential side effect against the drugs’ benefits in shared decision-making.
Ginger is highlighted as having multiple potential health benefits—from easing nausea (notably in pregnancy and after chemotherapy) to reducing inflammation and pain, improving cholesterol and blood sugar, and possibly supporting brain health and cancer research, though evidence is mixed and high doses can cause side effects or interact with certain medications; consult a clinician before taking supplements.
A new review in Trends in Endocrinology & Metabolism suggests fat quality—not total fat intake—may affect type 2 diabetes risk. Palmitic acid, a saturated fat common in meats, dairy and palm oil, can impair insulin action and promote inflammation, while oleic acid found in olive oil may help preserve insulin sensitivity. Diets high in unsaturated fats and patterns like the Mediterranean diet are linked to lower diabetes risk, though much evidence comes from lab and observational studies; more human trials are needed. Practical guidance: replace some saturated fats with heart-healthy fats (olive oil, nuts, seeds) and maintain a healthy lifestyle to reduce diabetes risk.
A study of about 59,000 adults with type 2 diabetes found semaglutide (the active ingredient in Ozempic/Wegovy) users had roughly 15% fewer bone fractures than peers on other weight‑loss meds (794 fractures among 26,324 semaglutide users vs 1,045 among 33,555 non‑semaglutide users), despite greater weight loss. The findings, presented at ENDO 2026, suggest a potential bone‑health benefit from semaglutide and underscore monitoring of bone health in weight‑loss therapies for older adults.
A study of 430 people in 207 households across Italy and Fiji shows that living under the same roof drives large-scale transfer of gut and oral bacterial strains, far exceeding genetic relatedness. Cohabitants share ~19% of gut and ~26% of oral strains, while romantically involved partners share about 44% of oral strains. Non-cohabiting individuals share markedly fewer strains. Importantly, the most transmissible gut bacteria correlate with biomarkers of Type 2 diabetes and poor cardiometabolic health, and certain oral strains linked to colorectal cancer. These findings could inform more effective probiotic and fecal microbiota transplant therapies by leveraging natural transmission traits.
A 2023 Mendelian randomization study using data from about 10,000 people found that genetically higher plasma caffeine concentrations are associated with lower BMI and fat mass, and a reduced risk of type 2 diabetes (about half of the effect mediated by BMI). There was no clear link to cardiovascular diseases. The authors note caffeine metabolism genes CYP1A2 and AHR influence caffeine levels, and suggest caffeine may boost thermogenesis and fat oxidation; however causal relationships aren’t proven and randomized trials are needed to confirm whether non-caloric caffeinated beverages could help reduce obesity or diabetes risk.
A study found four 60-second bursts of exercise—“exercise snacks”—throughout the day improved blood sugar control in people with Type 2 diabetes, suggesting that just four minutes of activity daily can help stabilize glucose.
A new review from the University of Barcelona finds that palmitic acid (a saturated fat) impairs insulin sensitivity and promotes inflammation, while oleic acid (a monounsaturated fat common in olive oil) improves insulin signaling and fat handling, suggesting fat quality matters more than total fat intake and helping explain the diabetes-protective associations of Mediterranean diets; more research is needed to resolve conflicting epidemiological results and consider fat source and processing.
New metabolomic and mouse studies show metformin lowers blood glucose by selectively inhibiting mitochondrial complex I in the intestinal epithelium, increasing intestinal glucose use and improving postprandial glycemic control, with raised levels of GDF15 and N-lactoyl-phenylalanine linked to systemic glucose regulation.
In ACHIEVE-4, the largest/longest Phase 3 trial of Foundayo (orforglipron) vs insulin glargine in adults with type 2 diabetes at high CV risk, Foundayo met non-inferiority for MACE-4 and showed 16% lower risk for MACE-4 and 23% lower risk for MACE-3; a pre-planned analysis also showed 57% lower risk of all-cause death. The study (2,700+ participants across 15 countries) demonstrated sustained A1C and body-weight improvements through 104 weeks. Lilly intends to submit Foundayo to the FDA for type 2 diabetes by end of Q2.
A 2024 umbrella review of 51 meta-analyses (covering about 270 blood-group–health links) finds only one robust association: blood type B has about a 28% higher risk of type 2 diabetes than non-B types; the effect is modest and far smaller than risk factors like diet, obesity, or inactivity, and researchers call for more rigorous work and study of potential mechanisms such as the gut microbiome; published in BMC Medicine.